The Oncologist · 2020 · 18 citations · 7 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunoregulationImmunotherapyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint ModulationImmune Checkpoint RegulationImmune CheckpointsDurable Clinical ResponseHodgkin Lymphoma TherapyImmune Checkpoint Inhibitor ResponseImmune Checkpoint Inhibitor TherapyLongitudinal ProgressionNon-hodgkin Lymphoma TherapyTime-to-treatment CompletionTreatment Progression
Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p = .035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p = .003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.
7
Philippe Armand, Andreas Engert, Anas Younes et al. · Journal of Clinical Oncology · 2018 · 754 citations · Full text
Medicine, Hematology, Oncology +17
Charles Herbaux, Jordan Gauthier, Pauline Brice et al. · Blood · 2017 · 216 citations
Life Sciences, Immunology, Oncology +11